Bradley K M, Bydder G M, Budge M M, Hajnal J V, White S J, Ripley B D, Smith A D
Oxford Project to Investigate Memory and Ageing, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK.
Br J Radiol. 2002 Jun;75(894):506-13. doi: 10.1259/bjr.75.894.750506.
A surrogate marker is needed for Alzheimer's disease (AD) both to aid diagnosis and to assess interventions. Despite widespread use, brain imaging markers have largely been confounded by overlap with "normal" ageing. 39 elderly subjects completed up to four serial volumetric brain MRI scans with intervals from 2.5 months to 7 months. By National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) criteria, five subjects had probable AD, two possible AD and 32 were negative for AD, although this group included memory-impaired subjects. Total brain and ventricular volumes were measured for each scan, and rates of change for each interval calculated. The rate of change in ventricle-to-brain ratio was 15.6% per year (standard deviation (SD) 2.8%) for probable AD compared with 4.3% per year (SD 1.1%) for negative AD (p<0.001). There was no significant difference between these groups' mean ventricle-to-brain ratios measured at a single time point (p=0.25). Rates of change in brain or ventricular volume over time also differed between the two groups (p<0.001). Power calculations reveal that to detect a 20% reduction in the excess rate of atrophy of a probable AD cohort in just 6 months, with 90% power, 135 subjects would be required in each arm of a randomized placebo controlled trial. For a 30% reduction in the excess rate of atrophy, 61 subjects would be required. Rate of change analysis makes serial brain MRI a valuable surrogate marker for Alzheimer's disease. Since only 6 months or less is required between scans, this procedure has both clinical relevance and potential for monitoring interventions.
阿尔茨海默病(AD)需要一种替代标志物来辅助诊断并评估干预措施。尽管脑成像标志物被广泛使用,但很大程度上因与“正常”衰老的重叠而混淆。39名老年受试者完成了多达四次连续的脑部容积MRI扫描,间隔时间为2.5个月至7个月。根据美国国立神经疾病与中风研究所(NINCDS)标准,5名受试者可能患有AD,2名可能患有AD,32名AD检测为阴性,尽管该组包括记忆受损的受试者。每次扫描均测量全脑和脑室容积,并计算每个间隔的变化率。可能患有AD的受试者脑室与脑比率的变化率为每年15.6%(标准差(SD)2.8%),而AD检测为阴性的受试者为每年4.3%(SD 1.1%)(p<0.001)。在单个时间点测量的这两组受试者的平均脑室与脑比率之间没有显著差异(p=0.25)。两组之间脑或脑室容积随时间的变化率也有所不同(p<0.001)。功效计算表明,在一项随机安慰剂对照试验的每组中,要在短短6个月内以90%的功效检测出可能患有AD的队列中萎缩率过高降低20%,则需要135名受试者。若萎缩率过高降低30%,则需要61名受试者。变化率分析使连续脑部MRI成为阿尔茨海默病的一种有价值的替代标志物。由于扫描之间仅需6个月或更短时间,该程序既具有临床相关性,又具有监测干预措施的潜力。